Phase I Trial Protocol Development
Budget: $15 – $25 USD
I am preparing a Phase I clinical trial and need an experienced hand to take charge of the protocol package from concept to final, submission-ready document. Your background in clinical trial management should translate my study objectives, inclusion/exclusion criteria, dose-escalation schema, and safety monitoring plan into a clear, regulator-friendly protocol.
Key deliverables:
• Full Phase I protocol (ICH-GCP compliant)
• Synopsis and schedule of assessments tables in editable format
• Integrated investigator brochure references and cross-links
• Version-controlled document history with tracked revisions
I will supply the core scientific rationale, pre-clinical data, and any existing templates. You will shape these into a cohesive protocol, ensure consistency with current FDA/EMA guidelines, and flag any gaps that might delay approval. Familiarity with tools such as MS Word (track changes), EndNote or similar reference managers, and basic statistical notation is essential.
A collaborative approach is important—I expect concise weekly progress updates and openness to feedback. If you have Phase I oncology or first-in-human experience, let me know; it will be a strong plus.
Final files should arrive ready for immediate inclusion in our regulatory submission package, along with a brief handover note summarizing assumptions and outstanding questions.
Key deliverables:
• Full Phase I protocol (ICH-GCP compliant)
• Synopsis and schedule of assessments tables in editable format
• Integrated investigator brochure references and cross-links
• Version-controlled document history with tracked revisions
I will supply the core scientific rationale, pre-clinical data, and any existing templates. You will shape these into a cohesive protocol, ensure consistency with current FDA/EMA guidelines, and flag any gaps that might delay approval. Familiarity with tools such as MS Word (track changes), EndNote or similar reference managers, and basic statistical notation is essential.
A collaborative approach is important—I expect concise weekly progress updates and openness to feedback. If you have Phase I oncology or first-in-human experience, let me know; it will be a strong plus.
Final files should arrive ready for immediate inclusion in our regulatory submission package, along with a brief handover note summarizing assumptions and outstanding questions.